Incannex Healthcare Limited

Incannex Healthcare Limited (IXHL) reported a net loss of $6.5 million for Q2 2026 (period ending December 31, 2025), with minimal revenue of $12,000. The loss was primarily driven by high operating expenses totaling $7.0 million, consisting of $2.3 million in research and development and $4.7 million in general and administrative costs. This was partially offset by other income of $474,000, including a $482,000 R&D tax incentive. The company's cash position strengthened significantly, with cash and cash equivalents reaching $68.9 million, bolstered by $71.7 million in proceeds from share issuance during the quarter. Total comprehensive loss was $6.8 million, including a $287,000 currency translation adjustment. The company continues to invest heavily in R&D while maintaining a strong liquidity position.

Key Takeaways